Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 5/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4670596 | 0.83 | LCK (0.36) | LCKPARP1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1229740 | 0.77 | KDM4E (0.43) | PARP1ALDH1A1KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL5749006 | 0.76 | KDM4E (0.54) | PARP1ALDH1A1KDM4ESMN1; SMN2HSD17B10 | |
| Hydrochloric Acid SCHEMBL8169298 | 0.75 | KDM4E (0.42) | PARP1ALDH1A1KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL4670559 | 0.71 | SLC2A1 (0.41) | ALDH1A1KDM4ESMN1; SMN2HSD17B10TSHR | |
| SCHEMBL2363489 | 0.70 | LCK (0.78) | LCKPARP1PLAUALDH1A1KDM4E | |
| SCHEMBL4578803 | 0.69 | ALDH1A1 (0.68) | LCKPARP1PLAUALDH1A1KDM4E | |
| SCHEMBL30935786 | 0.68 | LCK (0.75) | LCKPARP1PLAUALDH1A1KDM4E | |
| SCHEMBL4405181 | 0.68 | LCK (0.75) | LCKPARP1PLAUALDH1A1KDM4E | |
| SCHEMBL29463701 | 0.68 | ALDH1A1 (0.62) | LCKPARP1PLAUALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | claimed |
| EP-2534132-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | claimed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | claimed |
| CN-107847600-B | Combination therapy of anti-CD 20 antibodies with Bcl-2 inhibitors and MDM2 inhibitors | 豪夫迈·罗氏有限公司 | 2021-09-03 | — | — | CN | disclosed |
| EP-3302549-B1 | COMBINATION THERAPY OF AN ANTI CD20 ANTIBODY WITH A BCL-2 INHIBITOR AND A MDM2 INHIBITOR | HOFFMANN LA ROCHE (CH) | 2019-07-03 | — | — | EP | disclosed |
| EP-3302549-A1 | COMBINATION THERAPY OF AN ANTI CD20 ANTIBODY WITH A BCL-2 INHIBITOR AND A MDM2 INHIBITOR | H. Hoffnabb-La Roche Ag (CH) | 2018-04-11 | — | — | EP | disclosed |
| US-9657351-B2 | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist | HOFFMAN-LA ROCHE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2534132-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| WO-2016188935-A1 | COMBINATION THERAPY OF AN ANTI CD20 ANTIBODY WITH A BCL-2 INHIBITOR AND A MDM2 INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-01 | — | — | WO | disclosed |
| US-20160347852-A1 | Combination therapy of an anti-CD20 antibody with a Bcl-2 inhibitor and a MDM2 inhibitor | HOFFMANN-LA ROCHE INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-20150211073-A1 | MRNA-BASED GENE EXPRESSION FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST | HOFFMANN-LA ROCHE INC. | 2015-07-30 | — | — | US | disclosed |
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2534132-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | LCK 2395/4885PARP1 25/4885CSNK2A1 1074/4885 |
| US-20150211073-A1 | MRNA-BASED GENE EXPRESSION FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST | MDM2, TP53, TP53BP1 | LCK 3914/4885PARP1 270/4885CSNK2A1 1615/4885 |
| US-20160347852-A1 | Combination therapy of an anti-CD20 antibody with a Bcl-2 inhibitor and a MDM2 inhibitor | BCL2L1, MCL1, CD22 | LCK 896/4885PARP1 376/4885CSNK2A1 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.